ProCE Banner Activity

SGN35-015: Phase II Study of Frontline Brentuximab Vedotin ± Second Agent for Older Patients With cHL Ineligible for Standard CT

Slideset Download
Conference Coverage
Among patients with cHL and a median age of 74 years, frontline brentuximab vedotin therapy was associated with ORR > 90%.

Released: December 14, 2020

Expiration: December 13, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology